Electrocardiographic Changes in Hyperkalemia and Arrhythmia Risk

Hyperkalemia is a common and potentially reversible cause of conduction disturbance, bradyarrhythmia, ventricular tachycardia and cardiac arrest. Its electrocardiographic expression ranges from subtle T-wave changes to profound QRS widening and a pre-terminal sine-wave pattern. The apparent progression, however, is often less orderly than textbook diagrams suggest.

The ECG remains valuable because it is immediate, repeatable and available at the bedside while a serum potassium result is pending. It should never be treated as a reliable measure of potassium concentration. Some patients with severe hyperkalemia have limited ECG abnormalities, while others develop marked conduction changes after a relatively modest rise in measured potassium.

Clinical interpretation depends on the speed of change, renal function, acid–base status, medications, myocardial substrate and the presence of interacting electrolyte disturbances. A patient with chronic kidney disease may tolerate a higher potassium concentration than someone whose potassium has risen rapidly during acute kidney injury, tissue breakdown or medication toxicity.

For clinicians, electrophysiologists and trainees, the central issue is risk recognition: identifying when repolarisation abnormalities indicate a developing conduction emergency, when a tracing is falsely reassuring, and when immediate treatment should proceed before laboratory confirmation. The journal’s scope reflects this intersection of arrhythmia science, emergency care, devices and clinical electrophysiology.

Why Potassium Disturbs Cardiac Conduction

An elevated extracellular potassium concentration reduces the resting membrane potential of cardiac myocytes. Initially, this can increase membrane excitability and shorten repolarisation, producing tall, narrow, symmetrical T waves, particularly in the precordial leads. As depolarisation becomes progressively impaired, sodium-channel availability falls and conduction slows.

The familiar sequence of peaked T waves, PR prolongation, P-wave flattening or disappearance, QRS widening, fusion of the QRS complex with the T wave and sine-wave morphology is useful for teaching. It is not a dependable staging system for individual patients. Changes can appear out of sequence, fluctuate over time or be obscured by an underlying bundle branch block, ventricular pacing, left ventricular hypertrophy or myocardial ischaemia.

The ECG phenotype also reflects the rate of potassium change. Acute shifts may produce striking abnormalities before the absolute serum value becomes extreme. Chronic hyperkalemia can sometimes produce less dramatic changes, although this should never be interpreted as protection from ventricular arrhythmia. Acidosis, hypocalcaemia and sodium-channel-blocking drugs may further compromise conduction.

Recognising Early Repolarisation Abnormalities

The earliest visible feature is often a narrow, high-amplitude T wave with a pointed appearance. These waves are usually widespread rather than confined to a single coronary territory, though their distribution can vary. A broad-based T wave from myocardial ischaemia, a normal variant or ventricular hypertrophy can be mistaken for hyperkalemic tenting, so comparison with previous ECGs is particularly useful.

As potassium rises, the QT interval may appear shortened because the T wave begins earlier. The PR interval can lengthen, and P waves may become smaller or less distinct. These findings should be assessed in the full clinical context, with attention to lead placement, heart rate and rhythm. A single automated interpretation should not be allowed to overrule a concerning bedside assessment.

Serial ECGs are often more informative than one tracing. Repeating the test after an intervention can show whether membrane stabilisation and potassium-shifting therapy are having the expected effect, although ECG improvement does not prove that total body potassium has been removed. Continuous monitoring is appropriate for patients with significant hyperkalemia, ECG abnormalities, rapid biochemical change or major renal impairment.

When Conduction Slows and Arrhythmia Risk Escalates

Progressive hyperkalemia can cause first-degree atrioventricular block, sinoatrial dysfunction, junctional rhythms, high-grade AV block and severe bradycardia. P waves may disappear as atrial activity becomes electrically silent, while the QRS complex widens because intraventricular conduction is delayed. A broad-complex rhythm in this setting should be treated as potentially dangerous until reversible causes have been addressed.

The sine-wave pattern represents a severe loss of separation between depolarisation and repolarisation. It may precede ventricular fibrillation, pulseless electrical activity or asystole, but cardiac arrest can occur without this classic appearance. Ventricular tachycardia is less common than bradyarrhythmia and conduction failure, yet it remains a serious possibility, especially where hyperkalemia coexists with ischaemia, hypoxia or structural heart disease.

Risk assessment should therefore integrate the ECG with symptoms, haemodynamics and the trajectory of laboratory results. Syncope, weakness, paraesthesia, hypotension, new bradycardia, broadening QRS complexes or a changing rhythm demand urgent escalation. A patient who appears comfortable in triage may still deteriorate rapidly if potassium is continuing to rise.

Why the ECG and Serum Level May Disagree

The relationship between serum potassium and ECG severity is inconsistent. Measurement error from haemolysis, delayed sample processing or difficult venepuncture can produce pseudohyperkalemia. Conversely, a true result may underestimate the speed of intracellular-to-extracellular potassium movement. The ECG can be abnormal with a moderate reported concentration, while a patient with a higher result may have few visible changes.

A normal ECG cannot exclude clinically important hyperkalemia. Sensitivity is limited, especially in chronic kidney disease and in people with baseline conduction disease. A normal tracing should not delay treatment when the biochemical result, clinical setting and risk factors are strongly concerning. Repeating potassium through an appropriately collected sample can clarify uncertainty, but it should occur alongside monitoring rather than replace it.

Medication history deserves close attention. Renin–angiotensin–aldosterone system inhibitors, mineralocorticoid receptor antagonists, potassium-sparing diuretics, trimethoprim, non-steroidal anti-inflammatory drugs and potassium supplements can contribute. Digoxin toxicity, sodium-channel blockade, severe acidosis and hypocalcaemia may alter the ECG independently or magnify the effect of hyperkalemia.

Acute Management in Australian Practice

Marked ECG changes or a high-risk clinical presentation require an emergency response. Intravenous calcium is used to stabilise the myocardial membrane and reduce immediate electrical instability; it does not remove potassium from the body. Insulin with glucose, nebulised beta-2 agonist therapy and selected use of sodium bicarbonate can shift potassium intracellularly, with treatment choice guided by local protocols and the patient’s acid–base state.

Definitive potassium removal may require diuresis when renal function and volume status permit, potassium-binding therapy in selected circumstances, or urgent renal replacement therapy. Patients with refractory hyperkalemia, severe kidney failure, ongoing tissue breakdown or recurrent ECG changes need early nephrology and critical-care involvement. Glucose monitoring after insulin is essential because hypoglycaemia can occur after the potassium-lowering effect has begun.

Australian practice has practical variations that influence timing. A patient in a regional hospital in northern Queensland or rural New South Wales may need retrieval coordination while receiving immediate stabilisation, whereas an urban emergency department in Melbourne, Sydney or Perth may have rapid access to dialysis and cardiology support. Ambulance clinicians and hospital teams commonly refer to “the ambos” and must communicate the ECG trend, potassium result, renal function and therapies already given during transfer.

Remote and culturally diverse settings also require careful planning. Access to pathology, continuous monitoring and specialist advice may be limited in parts of the Northern Territory or Western Australia, making early escalation and clear retrieval pathways especially important. In Australia’s public health system, medication reconciliation, communication with the treating renal service and documentation of recurrent hyperkalemia can reduce the risk of repeated presentations.

Implications for Monitoring, Devices and Research

Hyperkalemia can mimic or aggravate device-related problems. A patient with a pacemaker may develop failure to capture, altered sensing or apparent pacing failure when myocardial excitability and conduction are severely disturbed. A broad paced QRS should not be dismissed as expected if there is a new change in capture threshold, underlying bradycardia or biochemical evidence of potassium elevation.

Implantable cardioverter-defibrillator therapies also require context. Hyperkalemia may produce oversensing, inappropriate detection or ventricular arrhythmias, while an arrhythmic event can occur before a device delivers therapy. Interrogation can help distinguish lead malfunction from a metabolic disturbance, but it must not delay emergency treatment of the patient’s physiology.

Research should move beyond the assumption that a single ECG feature can predict potassium concentration accurately. Useful areas include automated detection of subtle repolarisation changes, longitudinal analysis of serial ECGs, integration with renal function and medication data, and validation across different skin tones, ages, comorbidities and healthcare environments. Australian registries and retrieval networks could provide valuable data on time to treatment, rural access and outcomes after emergency hyperkalemia.

For clinical practice, a structured approach remains more dependable than memorising a rigid ECG sequence: confirm the rhythm and QRS width, compare with prior tracings, identify dynamic changes, assess haemodynamic stability, check potassium and renal function, review medications, and repeat the ECG after treatment. This framework supports rapid decisions while recognising the limitations of both the ECG and the laboratory result.

Clinicians managing patients at risk of hyperkalemia should incorporate serial ECG assessment into emergency pathways, renal reviews and device clinics, with clear escalation criteria for calcium, potassium-shifting therapy, specialist consultation and dialysis. Researchers and trainees can strengthen the evidence base by examining real-world arrhythmia patterns and treatment timing through peer-reviewed electrophysiology literature, while hospitals can use these findings to refine local protocols and retrieval communication.